Tags

Type your tag names separated by a space and hit enter

Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
J Dermatolog Treat. 2005 Feb; 16(1):10-4.JD

Abstract

Severe alopecia areata (AA) may have a chronic relapsing course and is often resistant to current treatments.

OBJECTIVES

The aim of our study was to evaluate whether topical immunotherapy with squaric acid dibutylester (SADBE) is able to improve the course of severe AA and to reduce the severity of relapses.

METHODS

Fifty-four patients affected by severe AA treated with SADBE who were followed for a period of at least 2 years were selected as the study group. Data collected were compared with those of a matched control group of 54 patients who did not receive any treatment. Student's t-test, analysis of variance (ANOVA) and Pearson's chi-squared test were utilized for data analysis.

RESULTS

At the end of therapy, in comparison with the control group, the treatment group showed a statistically significant (p < 0.001) improvement. At follow-up, there was no significant change in relapse rate (treated 44% vs control 52%). However, relapses in the treated group were significantly less severe compared with the control group (p < 0.001).

CONCLUSIONS

Our data suggest that topical SADBE represents a valid therapeutic option in severe AA, and may prove to be disease modifying.

Authors+Show Affiliations

Dall'oglio F
Dermatology Clinic, University of Catania, Catania, Italy.
Nasca MR
No affiliation info available
Musumeci ML
No affiliation info available
La Torre G
No affiliation info available
Ricciardi G
No affiliation info available
Potenza C
No affiliation info available
Micali G
No affiliation info available

MeSH

Adjuvants, ImmunologicAdolescentAdultAgedAlopecia AreataAnalysis of VarianceChi-Square DistributionChildChild, PreschoolCyclobutanesFemaleHumansMaleMiddle AgedTreatment Outcome

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

15897160

Citation

Dall'oglio, F, et al. "Topical Immunomodulator Therapy With Squaric Acid Dibutylester (SADBE) Is Effective Treatment for Severe Alopecia Areata (AA): Results of an Open-label, Paired-comparison, Clinical Trial." The Journal of Dermatological Treatment, vol. 16, no. 1, 2005, pp. 10-4.
Dall'oglio F, Nasca MR, Musumeci ML, et al. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. J Dermatolog Treat. 2005;16(1):10-4.
Dall'oglio, F., Nasca, M. R., Musumeci, M. L., La Torre, G., Ricciardi, G., Potenza, C., & Micali, G. (2005). Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. The Journal of Dermatological Treatment, 16(1), 10-4.
Dall'oglio F, et al. Topical Immunomodulator Therapy With Squaric Acid Dibutylester (SADBE) Is Effective Treatment for Severe Alopecia Areata (AA): Results of an Open-label, Paired-comparison, Clinical Trial. J Dermatolog Treat. 2005;16(1):10-4. PubMed PMID: 15897160.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial. AU - Dall'oglio,F, AU - Nasca,M R, AU - Musumeci,M L, AU - La Torre,G, AU - Ricciardi,G, AU - Potenza,C, AU - Micali,G, PY - 2005/5/18/pubmed PY - 2005/6/10/medline PY - 2005/5/18/entrez SP - 10 EP - 4 JF - The Journal of dermatological treatment JO - J Dermatolog Treat VL - 16 IS - 1 N2 - UNLABELLED: Severe alopecia areata (AA) may have a chronic relapsing course and is often resistant to current treatments. OBJECTIVES: The aim of our study was to evaluate whether topical immunotherapy with squaric acid dibutylester (SADBE) is able to improve the course of severe AA and to reduce the severity of relapses. METHODS: Fifty-four patients affected by severe AA treated with SADBE who were followed for a period of at least 2 years were selected as the study group. Data collected were compared with those of a matched control group of 54 patients who did not receive any treatment. Student's t-test, analysis of variance (ANOVA) and Pearson's chi-squared test were utilized for data analysis. RESULTS: At the end of therapy, in comparison with the control group, the treatment group showed a statistically significant (p < 0.001) improvement. At follow-up, there was no significant change in relapse rate (treated 44% vs control 52%). However, relapses in the treated group were significantly less severe compared with the control group (p < 0.001). CONCLUSIONS: Our data suggest that topical SADBE represents a valid therapeutic option in severe AA, and may prove to be disease modifying. SN - 0954-6634 UR - https://www.unboundmedicine.com/medline/citation/15897160/Topical_immunomodulator_therapy_with_squaric_acid_dibutylester__SADBE__is_effective_treatment_for_severe_alopecia_areata__AA_:_results_of_an_open_label_paired_comparison_clinical_trial_ DB - PRIME DP - Unbound Medicine ER -